ALKtALK Season 7 premieres Sunday, Sept. 27 at 7 p.m. ET with Dr. Eric Singhi @lungoncdoc of MD Anderson. Join us on Zoom for WCLC updates, practical information for life with ALK-positive cancer, and live Q&A. alkpositive.org/event/alktal… #ALKtALK #ALKPositive

8yr ADAURA update 🔥 informs cure vs delay-relapse debate 👉 77% pts surv data Overall: 8yr OS 79 v 64% HR 0.52 II-IIIA: 8yr OS 74 v 58% HR 0.53 🤔 Durable OS benefit ➡️ cure for some, albeit not for all ❓optimal Osi duration ❓risk stratification w MRD ❓sequencing #WCLC26

What IS the optimal treatment for a patient with locally advanced stage IIIA NSCLC with an ALK fusion? @StephenVLiu weighs in following a thoughtful discussion at the #BTGLung2026 meeting #lcsm @Georgetown @MedStarGUH @LombardiCancer

Dr @mal_itchins highlights 19 yrs of progress in ROS1 w latest data on zidesamtinib at #WCLC26. Congratulates work by @RO1ders @jfreemandaily Lilian Leigh @ProjectBreath. “12 yrs ago we didn’t test for ROS1 in Australia but thanks to a #clinicaltrial Lillian is still here today.”

Great to see more studies & focus on our EGFR exon 20 lung cancer population w presentations by @chulkimMD @danieltanmd and Dr Lyudmila Bazhenov at #WCLC26 @JillFeldman4 challenges on why data on reduced doses is not presented. Staying on treatment is key. Panel agrees

🆙 #WCLC26 #LCSM Mini Oral Session 🔥 A Pivotal Phase II Study of Ficonalkib, a 3rd-Generation ALK-TKI, in Advanced ALK-Positive NSCLC After 2nd-Generation ALK-TKI Failure 🎯ORR 43.1%, median PFS 9.7 mo, median DoR 15.2 mo 🎯Intracranial ORR 65.0% 🎯Most common TRAE diarrhea (71.9%); no neurologic toxicities 🎙️ Dr. Yuankai Shi 🔢 MO12.08 ☑️ NCT05869162 🔗 cattendee.abstractsonline.co… @OncoAlert @Larvol @IASLC @ALKPositiveinc

In a cancer community, grief takes many forms. 🎗️ #cancer #grief #lungcancer @OncogeneCancer

Mayya had cancer progression just 9 months into treatment for ALK+ lung cancer We celebrate advances in targeted therapies..but dont talk enough about those who progress early Progressing early on 1 therapy doesnt mean you won’t respond well to the next piped.video/tgVEx4lGMzo

The mRNA vaccine success vs melanoma in a Phase definitive 3 randomized trial today is on top of signs of success for personalized mRNA neoantigen vaccines vs pancreatic cancer, triple negative breast cancer, and non-small cell lung cancer wsj.com/health/pharma/modern…

👀 "Thinking about these toxicities is a very different scenario than thinking about most other toxicities, because they can be so acutely harmful depending on the circumstances," said David Gerber, MD, of @UTSWMedCenter on neurocognitive tradeoffs of later-generation ALK TKIs in NSCLC. Watch here ➡️: onclive.com/view/dr-gerber-o… #lcsm #oncology

At 38, Mayya had the dream family & career. Everything was going to plan. Then came a stage 4 ALK+ lung cancer diagnosis. Her first treatment worked. 8 months later, had wide progression. Read about what it’s like when you need to build a custom plan 👉 oncogeneresearch.org/mayyas-…

Join us Thursday, August 20, at 7 PM ET for Clinical Trials Connect! Hear about a year of progress in ALK research and treatment, followed by patient perspectives on participating in clinical trials. Join us: alkpositive.org/event/clinic… #ALKPositive #ClinicalTrials

Maybe that’s why oncolgists and hospitals are big fans of the @ALKPositiveinc community. We communicate well on a Facebook group and even built a trials finder into the ALKPositive.org website. We insta fill trials as they become available!

🫁 What's the latest on ALK+ NSCLC? 🌟 @Joshua_Reuss joined us for an insightful interview on key updates from #ASCO26, the most pressing remaining questions, and what the future may hold. ➡️ Watch now: buff.ly/0K6Vzar #lcsm #NSCLC #ALK

Grateful for the opportunity to join @CarmenMeccaPhD @NarjustFlorezMD to discuss emerging IO strategies in ALK+ lung cancer, including vaccines that may intercept ALK resistance mutations and advances in TCR therapy development. @chiarlelab @ALKPositiveinc @IASLC @hopkinskimmel

👏👏 Inspired by @SylvesterCancer #PatientAdvocate Nikki @eastbocaliving for sharing her incredible 5-year journey living with advanced ALK+ #LungCancer at the #ALKSummit in Washington, DC, this weekend. Her message: live in the present, make the most of every day, and lean into the people and moments that bring you joy. ❤️ @ALKPositiveinc #LungCancerAwareness

And finally, to the ALK-positive community: thank you for believing in this project long before there was much evidence that it would succeed. Your support made this work possible, and we hope this is just the beginning of a new way to develop medicines for patients.

in this work from the very beginning. John immediately recognized the potential of pursuing EML4-ALK and continually pushed us to explore the idea of converting existing drugs into COUPLrs. His vision, scientific instincts, and unwavering enthusiasm helped shape this project

More faces. More countries. One message. Where you live should never determine your chance of surviving lung cancer. #WLCD26 @YoungLungCancer @EGFRResisters @ALKPositiveinc

Pt 1 🌍 World Lung Cancer Day 2026- August 1st Lung cancer affects millions of people and families around the world. We shared faces from our community… along with unique lung cancer facts from around the globe. 🤍 #wlcd26 #lungcancer @OncogeneCancer @EGFRResisters